Outset Medical (OM) Q2 2026 Earnings Report

The call portrays a predominantly positive commercial and operational trajectory: modest year-over-year revenue growth with strong sequential momentum, meaningful gross margin expansion, a significant $40M refresh agreement with HCA that establishes backlog, a strengthened balance sheet with controlled cash burn, notable implementation and customer success achievements, and an encouraging pilot for next-gen Tablo expected to drive future refresh cycles. Offsetting this optimism are near-term softness in consumables (down 12%), a small decline in product and recurring revenue, continued non-GAAP operating losses, and inherent capital-sales timing variability. On balance, the company communicated improving fundamentals and clear strategic catalysts that outweigh current headwinds.

Outset reiterated full‑year 2026 revenue guidance of $125–$130 million (growth of ~5–9% vs. 2025), with most of the upside expected in Q3 and Q4 and management saying this outlook already factors in the $40 million HCA refresh agreement (extends through 2028). Supporting Q2 results included revenue of $31.6M (+1% YoY, +14% sequentially), console revenue $9.5M (+6% YoY), product revenue $21.9M (−5% YoY), consumables $12.4M (−12% YoY), recurring revenue $22.1M (−2% YoY), non‑GAAP gross margin 42.2% (on track to a 50% company‑wide milestone), non‑GAAP operating expenses $25.8M, non‑GAAP operating loss $12.4M (improved 7% YoY), ending cash of $151M, and Q2 cash use of $9.5M with the company on track to use < $40M for the full year. Management highlighted refresh tailwinds (an estimated refresh cycle of ~3,000 consoles and up to $150M in console revenue opportunity over the next several years), the next‑gen Tablo launch, and a formalized customer‑success program as drivers of future console, consumable and margin growth.